Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3712 - Comparison of clinical efficacy of SST analogues therapy (lanreotide Autogel vs. octreotide LAR) in treatment of patients with advance, non-resectable pancreatic neuroendocrine tumours(pNETs).


10 Sep 2017


Poster display session


Neuroendocrine Tumours


Agnieszka Kolasinska-Cwikla


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


A. Kolasinska-Cwikla1, A. Lewczuk2, J. Palucki1, L. Sawicki1, K. Roszkowska-Purska1, M. Kidd3, L. Bodei4, I. Modlin5, J. Cwikla6

Author affiliations

  • 1 Clinical Oncology, National Institute of Oncology-Marii Skodowskiej-Curie, 02-034 - Warsaw/PL
  • 2 Endocrinology, Medical Univeristy of Gdansk, 80-001 - Gdansk/PL
  • 3 Wren Laboratories, Wren Laboratories, 06405 - Branford/US
  • 4 Nuclear Medicine, European Institute of Oncology, Milan/IT
  • 5 Surgery Department, Yale University Scholl of Medicine, 065208062 - New Haven/US
  • 6 Radiology Department, Univeristy of Warmia and Mazury in Olsztyn, Faculty of Medical Sciences, 10-082 - Olsztyn/PL


Abstract 3712


Use of somatostatin analogues can be considered in pancreatic NET G1/G2 as a first-line therapy. This retrospective study aimed to compare the efficacy of octreotide long-acting release (OCT) and lanreotide Autogel (LAN) in patient with advanced G1/G2 pNETs, comparison between LAN and OCT in naïve patients, based on progression free survival (PFS).


Ninety-two patients with histological proven G1 or G2 pNETs were retrospectively analyzed (41 men; 51 women; mean age 53.7years [range 21-87 years]). The patients were assigned randomly to OCT (n = 42) and LAN (n = 50) groups. Evaluations included comparison of PFS between groups with LAN and OCT administered at 28-day intervals, objective response rate (ORR) calculated based on CT/MRI imaging performed every 6 month. The clinical efficacy was based on PFS and time to subsequent death/PD using Kaplan –Meier, radiological response was classified according to RECIST 1.0 criteria.


Medain PFS for all patients was 16.0 months (CI 22.8-34.9); in LAN group PFS 22 months (CI 21.9-39.5) vs OCT 15 (CI 18.1-35,1), P = 0.28 (Cox Mantel test). The significant difference was noted in group of patients with G2 tumors LAN 22 months (CI 19.5-35.0) vs. OCT 7 months (CI 8.2-22.2) P = 0.01. Even higher significant difference was obtained in males group G2: LAN 23.5 (CI 16-44.6) vs. OCT 6.0 months (CI 3.3-14.3). There was no significant difference in female patients: LAN 17.5 mo (CI 15.4-34.8) vs. OCT 13 months (CI 8.2-29.4), but the trend favorable LAN over OCT. Additional analysis in patients with liver metastasis showed similar trend, but no significant difference. There was no difference in PFS between groups with G1 tumors in male or female patients and those without liver involvement.


Lanreotide Autogel is preferable SST therapy in G2 pNET, especially in male patients. Additional it seems to be also more effective in female patients but without statistical significance. The trend of better efficacy in terms of increase PFS seems to be in favor of LAN in patients with liver involvement as well. There was no significant difference in groups of patients with G1 pNEN and those without liver involvement.

Clinical trial identification

Legal entity responsible for the study

Agnieszka Kolasinska-Cwikla




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.